- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Using a miniature laboratory-on-a-chip device, a team of investigators at the Massachusetts General Hospital, led by Daniel Haber, M.D., Ph.D., and Mehmet Toner, Ph.D., both members of the MIT-Harvard Center for Cancer Nanotechnology Excellence (CCNE), has developed a method that detects and analyzes the genetic signature of rare tumor cells in the bloodstream. The results from this analysis allowed the researchers to identify those patients most likely to respond to a specific targeted treatment. This chip-based analysis also allowed the researchers to monitor genetic changes that occur during therapy.
According to Dr. Haber, this chip opens up a new field of studying tumors in real time. "When the device is ready for larger clinical trials, it should give us new options for measuring treatment response, defining prognostic and predictive measures, and studying the biology of blood-borne metastasis, which is the primary method by which cancer spreads and becomes lethal." Dr. Haber and his team published their results in The New England Journal of Medicine.
Circulating tumor cells (CTCs) are living solid-tumor cells found at extremely low levels in the bloodstream. Until the development of the CTC-chip by the Massachusetts Institute of Technology (MIT)-Harvard CCNE team, it was not possible to get information from CTCs that would be useful for clinical decision-making. The current study was designed to determine whether the device could go beyond detecting CTCs to helping analyze the genetic mutations that can make a tumor sensitive to treatment with targeted therapy drugs.
The researchers tested blood samples from patients with non-small-cell lung cancer (NSCLC), the leading cause of cancer death in the United States. In 2004, cancer researchers had discovered that mutations in a protein called epidermal growth factor receptor (EGFR) determine whether NSCLC tumors respond to a group of drugs called tyrosine kinase inhibitors (TKIs), which includes gefitinib (Iressa) and erlotinib (Tarceva). Although the response of sensitive tumors to those drugs can be swift and dramatic, eventually many tumors become resistant to the drugs and resume growing.
The CTC-chip was used to analyze blood samples from 27 patients—23 who had EGFR mutations and 4 who did not—and CTCs were identified in samples from all patients. Genetic analysis of CTCs from mutation-positive tumors detected those mutations 92 percent of the time. In addition to the primary mutation that leads to initial tumor development and TKI sensitivity, the CTC-chip also detected a secondary mutation associated with treatment resistance in some participants, including those whose tumors originally responded to treatment but later resumed growing.
Blood samples were taken at regular intervals during the course of treatment from four patients with mutation-positive tumors. In all of those patients, levels of CTCs dropped sharply after TKI treatment began and began rising when tumors resumed growing. In one patient, adding additional chemotherapy caused CTC levels to drop again as the tumor continued shrinking.
Throughout the course of therapy, the tumors' genetic makeup continued to evolve. Not only did the most common resistance mutation emerge in tumors where it was not initially present, but new activating mutations—the type that causes a tumor to develop in the first place—appeared in seven patients' tumors, indicating that these cancers are more genetically complex than expected and that continuing to monitor tumor genotype throughout the course of treatment may be crucial.
"If tumor genotypes don't remain static during therapy, it's essential to know exactly what you're treating at the time you are treating it," says Haber. "Biopsy samples taken at the time of diagnosis can never tell us about changes emerging during therapy or genotypic differences that may occur in different sites of the original tumor, but the CTC-chip offers the promise of noninvasive continuous monitoring."
About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.
The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.
Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.
For more information, please click here
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
Copyright © National Cancer InstituteIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Nanoparticles that speed blood clotting may someday save lives August 23rd, 2016